NIR-II light triggered nitric oxide release nanoplatform combined chemo-photothermal therapy for overcoming multidrug...

Area of Science:

• Biomedical Engineering
• Materials Science
• Oncology

Background:

• Overexpression of P-glycoprotein (P-gp) in multidrug resistance (MDR) cancer cells leads to increased drug efflux, causing chemotherapy failure.
• Developing effective strategies to overcome MDR is crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To design and evaluate a near-infrared (NIR) light-responsive nitric oxide (NO) delivery nanoplatform for targeting MDR tumors.
• To combine chemotherapy, NO-mediated therapy, and photothermal therapy (PTT) for synergistic anticancer effects.

Main Methods:

• Fabrication of core-shell nanocomposites with a Cu2-xSe core and a mesoporous silica shell.
• Modification of the silica shell with a nitric oxide (NO) donor and folic acid (FA) for tumor targeting.
• Loading of doxorubicin (DOX) into the mesoporous silica shell for combination therapy.
• Evaluation of the nanoplatform's efficacy under NIR light irradiation for NO generation, P-gp inhibition, and PTT.

Main Results:

• The nanoplatform demonstrated high doxorubicin (DOX) encapsulation capacity.
• NIR light irradiation triggered nitric oxide (NO) generation, inhibiting P-glycoprotein (P-gp) expression and enhancing chemotherapeutic effects.
• The Cu2-xSe core facilitated photothermal therapy (PTT) by generating heat.
• The combined gas/chemo/PTT approach showed superior and synergistic efficacy in overcoming MDR cancer.

Conclusions:

• The developed nanoplatform offers an effective strategy for overcoming multidrug resistance (MDR) in cancer.
• This multifunctional nano-drug delivery system integrates diverse therapeutic modalities (NO delivery, chemotherapy, PTT) for enhanced cancer treatment.
• The study provides a promising approach for constructing advanced nanomedicine platforms for cancer therapy.